OBJECTIVES: Develop a value based framework using the Multi-Criteria Decision Analysis (MCDA) to evaluate oncology innovation from patient’s perspective.

METHODS: A Systematic Literature Review (SLR) was done focusing in four main questions: criteria used to assess the value of oncology innovation in general and from patient’s perspective, criteria used by HTAs and criteria used in previous MCDA projects from patient’s perspective. The EVIDEM framework was used to adapt the criteria gathered from the SLR into the Domains included in the framework. A working group composed by 8 patient’s representatives from General and Specific (disease) was asked to do the following task: 1. To assess and validate the criteria in the SLR, 2. To decide which criteria and definition of the criteria would be included or excluded from the proposed framework based on a general qualitative discussion among the panellist and 3. to weigh the agreed criteria in a 5-points scale from (1 no important to 5 most important).

RESULTS: We retrieved 757 articles and 47 were included. Only 2 additional criteria were included to EVIDEM framework (“cost-effectiveness” and “technological innovation”). Thus, we included 15 quantitative criteria and 7 contextual. The validation by patients excluded 4 quantitative (“technological innovation”; “cost effectiveness”; “quality of evidence” and “clinical practice guidelines”) and 2 contextual (“environmental impact” and “political, historical & cultural context”) and adapted the definitions of 3 quantitative ones. Ratings showed that most important criteria from patient’s perspective were “comparative patient-reported outcomes” (4.6) and “comparative efficacy/effectiveness” (4.6), the less important were “type of preventive reduction of risk” (2.9) and “comparative cost of intervention” (2.9).

CONCLUSIONS: A pilot MCDA framework was obtained with 11 quantitative and 5 contextual criteria to assess oncological innovation from patient’s perspective. Further research is ongoing to apply this scale in a pilot evaluation of oncology innovative therapies.